Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (752)	10/21/1998 8:01:00 PM
From: Rocketman	Read Replies (1) \| Respond to of 3202

Rick, THANKS!!! That is good enough that I'm going to copy it here: <<<<<<<< Note from the 10/12 issue of F-D-C Reports (The Pink Sheet)..... "Disputing cynicism about the impact of genomics, Ringrose reported that almost 60% 'of the targets that we have at Bristol-Myers Squibb now come from genomic databases'." Peter Ringrose is President of BMS PRI. >>>>>>>>> And, BMS is an INCY subscriber. Although Bristol was a bit later in the genomics game than many other pharmas, their view is that they were seeing how it sorted out and then using what other pharmas learned from their early efforts jumped in with both feet and are running with it. They have a major focus on it now and as the above quote attests they see it as a major source of their leads. This also gives some idea of how rich the INCY royalty stream will someday be. Rman